Loteprednol etabonate: Clinical potential in the management of ocular inflammation

BioDrugs

Volumn 10, Issue 4, 1998, Pages 329-339

  Noble, Stuart ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DELTA1 CORTIENIC ACID; DELTA1 CORTIENIC ACID ETABONATE; DRUG METABOLITE; LOTEPREDNOL ETABONATE; PLACEBO; PREDNISOLONE ACETATE; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; CATARACT EXTRACTION; CLINICAL TRIAL; CONTACT LENS; DRUG BLOOD LEVEL; DRUG DOSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EYE INFLAMMATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PAPILLARY CONJUNCTIVITIS; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0031795568     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810040-00007     Document Type: Review

References (33)

1. Howes JF. Development of soft drugs for ophthalmic use. In: Reddy IK, editor. Ocular therapeutics and drug delivery: a multidisciplinary approach. Lancaster (PA): Technomic Publishing Company, Inc., 1996: 363-74
2. Bodor N. Design of novel soft corticosteroids. Curr Probl Dermatol 1993; 21: 11-9
3. Bodor N. Designing safer ophthalmic drugs by soft drug approaches. J Ocul Pharmacol 1994; 10(1): 3-15
4. Lee HL, Iimoto DS, Takemoto KA. Subcellular distribution of esterases in the bovine eye. Curr Eye Res 1982/1983; 2(12): 869-76
5. Lee VHL, Smith RE. Effect of substrate concentration, product concentration, and peptides on the in vitro hydrolysis of model ester prodrugs by corneal esterases. J Ocul Pharmacol 1985; 1 (3): 269-78
6. Druzgala P, Hochhaus G, Bodor N. Soft drugs - 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol 1991 Feb; 38: 149-54
7. Abelson M, Howes J, George M. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 1998 (In press)
8. Reddy IK, Khan MA, Wu W-M, et al. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocul Pharmacol Ther 1996; 12 (2): 159-67
9. Druzgala P, Wu W-M, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991 Oct; 10: 933-7
10. Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite. PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1997; 14 (2): 153-8
11. Hochhaus G, Chien L-S, Ratka A, et al. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 1992 Dec; 81: 1210-5
12. Bodor N, Wu W-M, Murakami T, et al. Soft drugs 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 1995 Jun; 12: 875-9
13. Bodor N, Loftsson T, Wu W-m. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992 Oct; 9: 1275-8
14. Wu W-M, Murakami T, Angel S, et al. Pharmacokinetics, metabolism and excretion of a soft corticosteroid, loteprednol etabonate [abstract]. Pharm Res 1992 Oct; 9 (Suppl): S295
15. Wu W-M, Bodor N. Metabolism and excretion of loteprednol etabonate, a soft corticosteroid, in rats [abstract]. Pharm Res 1994 Oct; 11 Suppl.: 364
16. Stewart R, Horwitz B, Howes J, et al. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. J Cataract Refract Surg 1998 (In press)
17. The Loteprednol Etabonate Post-operative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. Ophthalmology 1998 (In press)
18. Dell SJ, Shulman DG, Lowry GM, et al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1997 Jun; 123: 791-7
19. Dell SJ, Lowry G, Northcutt JA, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998 Aug; 102 (2): 251-5
20. Shulman DG, Lothringer HL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1998 (In press)
21. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993 Apr; 12: 313-21
22. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol 1997 Apr; 123: 455-64
23. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997 Jan; 23: 31-6
24. Raizman M. Corticosteroid therapy of eye disease: Fifty years later. Arch Ophthalmol 1996; 114 (8): 1000-1
25. Novack GD, Howes J, Crockett RS, et al. Change in intraocular pressure during chronic use of loteprednol etabonate. J Glaucoma 1998. In press
26. Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993 Summer; 9: 157-65
27. Bausch & Lomb Pharmaceuticals Inc. Lotemax™ loteprednol etabonate ophthalmic suspension, 0.5%. Prescribing information. Tampa (FL), USA, 1998
28. Bausch & Lomb Pharmaceutical. Alrex™ loteprednol etabonate ophthalmic suspension, 0.2%. Prescribing information. Tampa (FL), USA, 1998
29. Ciprandi G, Buscaglia S, Canonica GW. Management of allergic conjunctivitis. Clin Immunother 1996 May; 5: 374-91
30. Allansmith MR. Giant papillary conjunctivitis. J Am Optom Assoc 1990; 61 (6) Suppl.: S42-46
31. Allansmith MR, Ross RN, Greiner JV. Giant papillary conjunctivitis: diagnosis and treatment. In: Dabezies Jr OH, Cavanagh HD, Farris RL, et al., editors. Contact lenses: the CLAO guide to basic science and clinical practice, 2nd ed. Boston: Little, Brown and Company, 1984; 43.1-43.17
32. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986 Jan/Feb; 30 (4): 229-44
33. Asbell PA, Torres MA. Therapeutic dilemmas in external ocular diseases. Drugs 1991 Oct; 42: 606-15